Brains Aged Faster In 2021–2022: What Did The Pandemic Do To Us?
Leveraging an extensive database of brain scans, British researchers say that people's brains showed accelerated aging during 2021 and 2022, including signs of shrinkage.
While people who were infected with COVID also showed cognitive decline, like slower processing speed, the study was notable because it said even the non-infected were likely to experience harm to their brain.
While the study did not delve into the exact causes of the accelerated aging, the study's first author, Ali-Reza Mohammadi-Nejad, a neuroimaging researcher at the University of Nottingham, theorizes that it may have been the result of stress and other factors.
'But it is likely that the cumulative experience of the pandemic—including psychological stress, social isolation, disruptions in daily life, reduced activity and wellness—contributed to the observed changes… In this sense, the pandemic period itself appears to have left a mark on our brains, even in the absence of infection,' said Mohammadi-Nejad, per NBC.
The researchers found that males and 'those from more socioeconomically deprived backgrounds' experienced the most significant brain aging. Overall, the pandemic was thought to be linked to a 5.5-month acceleration in the aging process.
This is not the first time researchers have reached similar conclusions.
Last year, a previous study found that teenagers experienced dramatic brain aging during the pandemic. Notably, the study suggested that girls' brains aged 4.2 years faster and boys' brains aged 1.3 years faster, on average.
The latest study does not indicate whether the structural changes identified in individuals who have never contracted COVID will result in any noticeable changes in brain function. Nor does the study confirm whether the physical changes will persist over the long term, says Adam Brickman, a professor of neuropsychology at Columbia University Vagelos College of Physicians and Surgeons, who was not involved in the study.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Scientists Found a Hidden Code in the Human Genome
Here's what you'll learn when you read this story: Around 45 percent of human DNA is made up of transposable elements, or TEs—genetic leftovers from now-extinct viruses that scientists once believed to be 'junk DNA.' But that view is changing, and a new study—which grouped TEs based on evolutionary relationships and level of conservation—found that one family of sequences known as MER11 plays a role in gene expression. Nearly 80 years after their initial discovery, scientists are still finding new things about how TEs play a vital role in primate evolution. Ever since Swiss physician Friedrich Miescher first isolated DNA back in 1869, science has been on an incredible path of genomic discovery. One of the major moments in the journey occurred in the 1940s, when cytogeneticist Barbara McClintock discovered transposable elements (TE), also known as 'jumping genes.' Decades later, The Human Genome Project found that these elements made up a staggering 45 percent of the human genome, and managed to proliferate over millions of years thanks to a 'copy-and-paste' mechanism. Because these sequences are highly repetitive and nearly identical, they've been disregarded as 'junk DNA' for decades—genetic leftovers from long-extinct viruses. But in recent years, this unflattering view of these sequences has begun to change. Today, scientists believe that TEs play a role in genome function, chromosome evolution, speciation, and diversity. However, due to their repetitive nature, TEs remain difficult to research. Now, a new international study has found a novel method for analyzing these mysterious sequences, and they've discovered hidden patterns responsible for gene expression. The results of the study were published in the journal Science Advances. 'Our genome was sequenced long ago, but the function of many of its parts remain unknown,' Fumitaka Inoue, a co-author of the study from Kyoto University, said in a press statement. Understanding TEs would solve one of the biggest mysteries of the genome. In an attempt to better understand TEs, the researchers developed a new method for classifying them. Eschewing standard annotation tools, this study groups TEs based on both their evolutionary relationships and their conservation quality in the primate genome. Focusing on a family of sequences called MER11, the new method allowed scientists to divide the group into subgroups, named MER11_G1 through G4. The G1 subgroup represented the oldest evolutionary sequences, while G4 contained the youngest. By looking at MER11 through this new lens, researchers were able to compare these new subfamilies with epigenetic markers, and found that these groups appeared to have a regulatory function within the genome. In other words, they acted like on-off switches for gene expression—particularly in early human development. Of course, it's one thing to infer a pattern, and another to see it in action. So, the team used a technique known as 'lentiviral massively parallel reporter assay,' or lentiMPRA, to measure 7,000 MER11 sequences using human stem cells and early-stage neural cells. This showed that the youngest of the group (MER11_G4) had the strongest impact on gene expression. According to the study, this group makes use of regulatory 'motifs'—short stretches of DNA that influence gene development and response. By tracking the evolution of this group, scientists have shown that DNA originally inherited from ancient viruses can actively participate in the form and function of primate DNA. Even though the journey of understanding the human genome is more than 150 years in the making, it still has the remarkable ability to surprise us at seemingly every turn. You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50 Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Hundreds of budding footballers gather in 'landmark day for women's sport'
HUNDREDS of budding footballers gathered in Glasgow over the weekend in a 'landmark day for women's sport'. More than 200 girls from across the West of Scotland arrived at Petershill Park in Springburn on Sunday, July 27, for the annual Turner Syndrome Awareness Football Festival. For the first time, teams had the chance to play across the entire complex in North Glasgow, which allowed even more girls to take part. (Image: TSSS) The event was organised by the Turner Syndrome Support Society (TSSS) in an effort to raise awareness of the rare genetic condition, which is said to affect one in every 2000 girls. Arlene Smyth, executive officer of the TSSS, highlighted the importance of early diagnosis. She said: "Events like these are absolutely essential in raising awareness of Turner Syndrome. "If a girl is not achieving expected growth or development, it's important not to ignore the signs -early diagnosis makes a real difference. 'We're grateful to everyone who helped make today possible." (Image: TSSS) READ NEXT: According to NHS Scotland, Turner Syndrome (TS) is a rare genetic condition that only affects females and is usually diagnosed at birth. There is currently no cure, but treatment and support are available to help manage symptoms. It is understood that everyone with the condition is affected differently; however, it can impact growth, height, and general development. This year's football festival saw an increase of more than 50 per cent in attendance and was described as both a 'significant milestone' for girls' football and raising awareness of TS. Teams from Phoenix Girls travelled from Hamilton, Renfrew, West Park United, Kilmarnock and Glasgow City to take part. Gus MacLean, chair of Phoenix Girls FC, said: "This event wouldn't have been possible without the commitment of our partners, the Partick Thistle Charitable Trust, and the tireless work of coaches, parents, and volunteers. 'Together, we're making a real difference." Iain Stuart, Scottish Women's Premier League competitions officer, presented the medals on the day. (Image: TSSS) He praised the event as a 'testament' to the power of partnership and community. READ NEXT: Speaking at the festival, Mr Stuart commented: "Festivals like this simply didn't exist a decade ago. "It's fantastic to see hundreds of girls out playing football together, raising awareness, and showing just how far the women's game has come. 'Today is a testament to the power of partnership and community." The event was delivered through a partnership between the TSSS, a Clydebank-based charity, and Phoenix Girls FC, who built on the previous year's success with the support of the [[Partick Thistle]] Charitable Trust. (Image: TSSS) (Image: TSSS) It was dedicated to the memory of Emma Woods, who lived with TS and sadly died aged 20. The Emma Woods Memorial Fund, created by her friends and family, continues to raise vital funds to support awareness campaigns and initiatives such as the festival. Fraser Cromar, CEO of the Partick Thistle Charitable Trust, said: "Petershill Park is synonymous with women's football in Scotland, being home to both Glasgow City and Partick Thistle Women. 'When we heard about the vision behind the Turner Syndrome Awareness Football Festival, we were fully committed to supporting it. 'Bringing communities together through football to raise awareness for such an important cause is exactly the kind of initiative we want to champion." For further information on TS visit the TSSS's website HERE.
Medscape
an hour ago
- Medscape
EMA Committee Backs Tryngolza for Rare Lipid Disorder
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization in the European Union to Tryngolza (olezarsen; Ionis Ireland Limited) for treating adults with familial chylomicronemia syndrome (FCS). The drug, to be available as an 80-mg solution for injection in prefilled pens, will be used as an adjunct to dietary modifications in adult patients with genetically confirmed FCS. FCS is a rare inherited disorder caused by loss-of-function variants in LPL or related genes, leading to absent or severely reduced lipoprotein lipase activity. This results in extreme hypertriglyceridemia (often > 880 mg/dL or 10 mmol/L) due to accumulation of chylomicrons and very low-density lipoprotein (VLDL). FCS affects about 13 people per million in Europe and causes recurrent acute pancreatitis (in about 85% of patients), severe abdominal pain, and chronic complications. Standard lipid-lowering therapies are typically ineffective, and strict fat-restricted diets are difficult to maintain, making disease management challenging. Tryngolza, a lipid-modifying agent, is an antisense oligonucleotide-GalNAc₃ carbohydrate ligand conjugate that targets apolipoprotein C-III (apoC-III) mRNA in hepatocytes. The GalNAc₃ moiety facilitates selective uptake by liver cells and, once internalized, the antisense oligonucleotide blocks apoC-III protein synthesis. This enhances lipolysis and hepatic clearance of triglyceride-rich lipoproteins, including VLDL and chylomicrons, ultimately lowering plasma triglyceride levels. Significant Benefits in Clinical Trials The CHMP decision relied on positive findings from the phase 3 Balance trial involving 66 patients with genetically confirmed FCS and severe hypertriglyceridemia, including 71% with a history of acute pancreatitis. Participants were randomly assigned to receive Tryngolza 80 mg, 50 mg, or placebo subcutaneous injections every 4 weeks for 49 weeks. Tryngolza 80 mg significantly reduced triglyceride levels by 43.5 percentage points at 6 months compared with placebo, while the 50-mg dose showed a nonsignificant reduction. Both doses markedly decreased apoC-III concentrations, with the 80-mg group achieving a 73.7-percentage point drop and the 50-mg group a 65.5-percentage point decline vs placebo. Acute pancreatitis events decreased significantly, with 11 episodes occurring among placebo recipients compared with just one in each Tryngolza group over 53 weeks, indicating an 88% risk reduction. The most common side effects of Tryngolza include injection-site erythema, headache, arthralgia, and vomiting.
